MRD (Minimal Residual Disease) Testing Market Size, Share & Trends Analysis Report By Product (Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)), By Applications (Specialty Clinics and Hospitals, Diagnostic Laboratories, Research Institutions), By End Use, By Region, and Segment Forecasts - 2035

MRD (Minimal Residual Disease) Testing Market Overview

The mrd (minimal residual disease) testing market size is expected to grow from USD 1954.63 million in 2025 to USD 2251.54 million in 2026 and is forecast to reach USD 3441.3 million by 2035 at 15.19% CAGR over 2026-2035.

MRD testing is moving from a specialized hematology assessment toward a broader precision-oncology tool as laboratories improve detection of extremely small malignant cell populations after treatment. Flow cytometry remains an established clinical technology and represented approximately 40-43% of technology-based demand in recent industry assessments, while Next-Generation Sequencing (NGS) is gaining importance because personalized assays can monitor multiple tumor-associated variants simultaneously. Clinical adoption is also being strengthened by the expanding cancer population: approximately 2.04 million new cancer cases were expected in the United States during 2025, including about 66,890 leukemia cases and 80,350 non-Hodgkin lymphoma cases. The increasing number of survivors requiring post-treatment surveillance further supports repeated MRD assessment, with the U.S. cancer survivor population estimated at approximately 18.6 million in early 2025 and projected to approach 22 million by 2035.

The United States represents the most developed national environment for MRD testing, supported by advanced molecular laboratories, established oncology networks and accelerating regulatory acceptance of circulating tumor DNA monitoring. The country has accounted for close to 40% of global MRD testing activity in recent industry assessments, while North America represented approximately 46.2% of the broader market in 2024. A significant regulatory milestone occurred in May 2026 when a personalized circulating tumor DNA MRD assay received U.S. companion diagnostic approval for treatment selection in muscle-invasive bladder cancer. This development expands MRD beyond recurrence surveillance toward therapy-guiding applications and is likely to encourage additional prospective studies across solid tumors.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Flow Cytometry remains the leading supplied product type, supported by established hematology workflows and approximately 42.7% share reported in recent technology assessments, while its rapid multiparameter analysis sustains routine leukemia and lymphoma monitoring.
• Leading Application: Specialty Clinics and Hospitals represent the leading application environment as oncologists increasingly incorporate MRD status into treatment decisions, with more than 70% of hematologic cancer treatment pathways in advanced settings reported to incorporate MRD-related information.
• Leading Region: North America leads MRD testing adoption, supported by advanced molecular diagnostics, reimbursement infrastructure and concentrated precision-oncology activity, with the region accounting for approximately 46.2% of global market activity in a recent annual assessment.
• Fastest Growing Region: Asia-Pacific is projected to record the fastest expansion as China, India, Japan and other healthcare systems increase molecular testing capacity, with regional growth indicators reaching approximately 14.2% CAGR across recent industry forecasts.
• Technology Trend: NGS-based MRD testing is advancing toward ultra-sensitive personalized monitoring, with emerging platforms capable of tracking hundreds or even more than 1,000 tumor-associated variants compared with approximately 16-50 variants in several earlier-generation approaches.
• Market Driver: Expanding cancer surveillance requirements remain a major demand catalyst, as the United States recorded an estimated 2,041,910 new cancer diagnoses in 2025, creating a substantial population requiring treatment-response assessment and recurrence monitoring.
• Competitive Landscape: Competition is shifting toward regulatory validation and therapy-guiding assays, highlighted in 2026 by the first U.S. companion diagnostic approval for a personalized blood-based MRD test, creating a new commercial pathway for precision-oncology companies.
• Future Outlook: MRD testing will increasingly extend from hematologic malignancies into solid-tumor surveillance and treatment selection, supported by a U.S. cancer survivor population expected to increase from approximately 18.6 million in 2025 to 22 million by 2035.

Latest Trends

The most important technological trend is the transition from single-marker or relatively narrow molecular monitoring toward highly multiplexed NGS and circulating tumor DNA analysis. Traditional flow cytometry can reach clinically meaningful sensitivity in hematologic malignancies while maintaining fast turnaround, but personalized NGS approaches are increasingly designed to detect tumor fractions near or below 0.01%. Newer platforms can follow hundreds or thousands of tumor-specific variants, compared with approximately 16-50 mutations evaluated by several earlier blood-based approaches. This increase in molecular breadth is particularly important after surgery or systemic treatment, when residual tumor DNA can occur at extremely low concentrations. The trend is also encouraging hybrid analytical strategies incorporating genomic variants, methylation patterns and fragment characteristics to improve detection in tumors that release relatively little circulating DNA.

A second major trend is the transformation of MRD status from a monitoring measurement into an actionable treatment biomarker. The May 2026 U.S. approval of a personalized circulating tumor DNA assay as a companion diagnostic in muscle-invasive bladder cancer represented the first regulatory milestone of its type for blood-based MRD-guided treatment. This development is strategically important because it connects a positive or negative MRD result directly with therapeutic decision-making rather than using the result only to estimate recurrence risk. At the same time, tissue-free testing is expanding the addressable patient population; emerging tissue-free approaches have demonstrated detection performance equivalent to roughly 86% of corresponding tumor-informed testing in selected evaluations. These advances are encouraging pharmaceutical companies to embed serial MRD measurements into oncology trials and potentially use molecular response as an earlier indicator of therapeutic effectiveness.

Market Dynamics

Driver

""Rising cancer survivorship and precision oncology are accelerating routine MRD monitoring.""

The principal driver is the growing need to identify residual malignant disease before recurrence becomes clinically or radiographically evident. Approximately 18.6 million people were living after a cancer diagnosis in the United States at the beginning of 2025, representing slightly more than 5% of the population, and this survivor population is expected to reach approximately 22 million by 2035. The surveillance opportunity is particularly relevant to hematologic malignancies: the United States recorded an estimated 66,890 new leukemia cases and 80,350 non-Hodgkin lymphoma cases during 2025. As survival improves, a larger patient pool requires repeated post-treatment assessment, increasing test frequency rather than creating only one-time diagnostic demand. MRD measurements can also help clinicians distinguish patients who may benefit from intensified therapy from those who could potentially avoid unnecessary treatment, making testing increasingly compatible with risk-adapted oncology.

Regulatory acceptance provides an additional demand catalyst. During 2026, blood-based MRD achieved a major transition into companion diagnostic use in the United States, demonstrating that molecular residual disease can become part of a formal treatment-selection pathway. This milestone follows years of clinical evidence connecting persistent MRD positivity with increased relapse risk across multiple malignancies. The result is a market increasingly supported by 3 interconnected demand streams: routine clinical surveillance, pharmaceutical clinical trials and therapy-selection programs. As more prospective trials incorporate molecular response endpoints, assay providers gain opportunities for repeated sample analysis at baseline, post-treatment and longitudinal follow-up stages.

Restraint

""High analytical complexity and uneven access restrict broader clinical penetration.""

Advanced MRD testing requires specialized sequencing infrastructure, validated bioinformatics, high-quality sample handling and trained molecular pathology personnel, limiting adoption outside major cancer centers. Access disparities remain particularly significant in developing healthcare systems, where only a minority of laboratories possess the equipment and quality-control capabilities required for highly sensitive molecular monitoring. Flow Cytometry partially addresses this constraint because it is already established across many hematology laboratories and represented approximately 42.7% of global technology demand in one recent assessment. However, even flow-based MRD testing requires standardized antibody panels, experienced interpretation and rigorous specimen preparation. For NGS, sensitivity requirements can approach tumor fractions around 0.01% or lower, meaning sequencing errors, inadequate DNA input and pre-analytical variability can materially affect clinical interpretation.

Reimbursement uncertainty also slows testing frequency. MRD surveillance can involve multiple assessments over a treatment course rather than a single laboratory procedure, creating greater payer scrutiny around clinical utility and testing intervals. Adoption is therefore strongest in regions with sophisticated oncology reimbursement and weakest where molecular diagnostics remain predominantly self-funded. The difference is visible geographically: North America accounted for approximately 46.2% of global activity in a recent assessment, whereas emerging markets remain considerably less penetrated despite rapidly increasing cancer incidence. Until standardized guidelines, payer policies and evidence-based testing schedules become more consistent, advanced assays may remain concentrated in tertiary hospitals and specialized laboratories.

Opportunity

""Solid-tumor MRD and liquid biopsy applications create a major expansion pathway.""

The largest emerging opportunity is extending MRD beyond traditional blood cancers into solid tumors, where the potential surveillance population is substantially larger. In the United States alone, approximately 154,270 colorectal cancer cases, 84,870 bladder cancer cases and 226,650 lung cancer cases were expected during 2025. Even partial penetration of post-treatment monitoring across these disease groups could materially increase testing volumes because surveillance frequently requires serial blood collection over several years. Liquid biopsy approaches are especially attractive because they can reduce dependence on repeated invasive tissue procedures and potentially detect molecular recurrence months before conventional imaging in selected patients. Some clinical studies have demonstrated molecular signals more than 20 months before radiographic recurrence in individual settings, illustrating the potential clinical value of earlier intervention.

Asia-Pacific provides another substantial opportunity as governments and private healthcare providers expand genomic laboratory capacity. Regional MRD demand is projected to advance at approximately 14.2% CAGR in recent forecasts, while India-specific assessments indicate growth of around 15.5% through the early 2030s. China is expected to remain the largest Asia-Pacific contributor, supported by large cancer populations, expanding sequencing infrastructure and increasing participation in oncology clinical trials. This environment creates opportunities for companies offering scalable NGS workflows, PCR platforms and standardized Flow Cytometry solutions that can be deployed beyond flagship academic hospitals.

Challenge

""Assay standardization and ultra-low disease detection remain technically demanding.""

The central technical challenge is reliably distinguishing true residual cancer signals from biological background and analytical noise at extremely low disease levels. Advanced assays increasingly target tumor fractions near 0.01%, while newer research platforms are pursuing detection around 1 cancer-associated fragment among approximately 1 million background DNA fragments. Performance can vary according to tumor biology because some cancers release substantially less circulating DNA than others. A negative result therefore does not always mean complete disease eradication, especially when sample volume is limited or the tumor is a low-shedding phenotype. This creates a requirement for longitudinal testing and careful clinical interpretation rather than reliance on a single measurement.

Cross-platform comparability is another challenge because Flow Cytometry, Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS) measure residual disease through different biological and analytical mechanisms. Flow cytometry held approximately 40% of technology demand in 2025 assessments, yet NGS is projected to expand faster because of increasing sensitivity and personalized tracking capabilities. Laboratories consequently face decisions around platform migration, validation and interoperability. Standardized thresholds, reference materials and reporting terminology will become increasingly important as MRD results influence treatment decisions, particularly following the 2026 emergence of formal companion diagnostic applications.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Flow Cytometry: Flow Cytometry represents the largest established technology category, with recent market assessments placing its share at approximately 42.7% globally and around 40.9% in North America during comparable periods. Its strength comes from rapid multiparameter characterization of abnormal cells, extensive use in leukemia and lymphoma laboratories and comparatively mature clinical workflows. Modern multiparameter systems can evaluate 8 or more cellular markers simultaneously, allowing laboratories to identify rare abnormal populations against normal hematopoietic backgrounds. The technology remains particularly competitive where bone marrow samples are routinely collected and rapid turnaround is required.

Polymerase Chain Reaction (PCR): Polymerase Chain Reaction (PCR) remains a clinically important MRD technology and is estimated to account for approximately 25-30% of supplied-technology demand across established testing environments. PCR workflows are particularly effective when a known molecular target can be monitored with high analytical sensitivity. Quantitative and digital approaches can identify low-frequency disease-associated sequences and provide relatively focused workflows compared with broad sequencing. PCR continues to benefit from a large installed molecular-diagnostics base, while its principal limitation is that individual assays generally monitor fewer molecular targets than modern NGS approaches.

Next-Generation Sequencing (NGS): Next-Generation Sequencing (NGS) is estimated to represent approximately 30-35% of current supplied-technology demand and is projected to gain share fastest through 2035. Its competitive advantage is increasing analytical depth: contemporary personalized approaches can track hundreds or more than 1,000 tumor-associated variants, whereas earlier-generation molecular tests frequently evaluated approximately 16-50 mutations. NGS also supports longitudinal circulating tumor DNA assessment and can extend MRD testing into solid tumors. As sequencing costs decline and automated bioinformatics improve, NGS is positioned to capture incremental testing from both PCR and centralized research workflows.

By Applications

Specialty Clinics and Hospitals: Specialty Clinics and Hospitals represent the leading application segment, estimated at approximately 50-55% of testing demand because they concentrate oncology treatment, bone marrow procedures, surgical follow-up and therapeutic decision-making. Their leadership is reinforced by the growing clinical relevance of MRD status, with more than 70% of hematologic cancer treatment pathways in advanced care environments reported to incorporate MRD information. Hospitals also provide direct access to multidisciplinary tumor boards and specialists capable of interpreting molecular findings alongside imaging and pathology results.

Diagnostic Laboratories: Diagnostic Laboratories are estimated to account for approximately 30-35% of application demand and are becoming more strategically important as high-complexity molecular assays centralize within specialized facilities. NGS-based MRD testing requires sequencing platforms, bioinformatics and quality systems that many individual clinics cannot economically maintain. Central laboratories can process thousands of samples using standardized workflows and provide testing across multiple geographic areas. The growing adoption of blood-based assays further supports laboratory centralization because plasma samples can be transported more easily than many invasive tissue specimens.

Research Institutions: Research Institutions represent approximately 15-20% of current application demand but exert disproportionate influence over technology development and clinical validation. MRD is increasingly incorporated into oncology studies as an exploratory, secondary or treatment-response endpoint, and clinical research programs frequently collect 3 or more longitudinal samples from individual participants. Academic institutions are also evaluating methylation, fragmentomics and highly multiplexed sequencing approaches capable of detecting extremely low circulating tumor DNA concentrations. Research demand therefore acts as an important commercialization bridge for technologies that may later enter routine clinical practice.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America remains the leading MRD testing region, accounting for approximately 46.2% of global activity in a recent annual assessment. The United States drives regional demand through advanced oncology networks, widespread molecular laboratory capacity, strong clinical-trial participation and a large cancer surveillance population. Approximately 2.04 million new cancer cases were expected nationally during 2025, while the survivor population reached approximately 18.6 million. These figures create substantial recurring demand for molecular monitoring after surgery, chemotherapy, immunotherapy and transplantation. The region also benefits from high adoption of Flow Cytometry, which accounted for approximately 40.9% of technology activity in a recent North American assessment.

The regulatory environment strengthened further in 2026 when personalized circulating tumor DNA MRD testing obtained a U.S. companion diagnostic role in muscle-invasive bladder cancer. This represents an important shift from prognostic surveillance toward treatment-guiding use. The region is also home to a substantial proportion of the supplied competitive set, including Natera, NeoGenomics Laboratories, Asuragen, Invivoscribe, Bio-Rad Laboratories, ARUP Laboratories, Guardant Health, Adaptive Biotechnologie, Mission Bio, LabCorp, Quest Diagnostics and Opko Health. With the U.S. cancer survivor population projected to reach approximately 22 million by 2035, longitudinal monitoring should remain a major regional growth engine.

Europe

Europe represents the second major MRD testing region, supported by national cancer programs, academic hematology networks and widespread adoption of molecular diagnostics. Flow Cytometry represented approximately 40.8% of regional technology demand in a recent 2025 assessment, demonstrating that established cellular analysis remains central to European MRD practice even as NGS adoption accelerates. Major healthcare systems in Germany, France, the United Kingdom, Italy, Spain and the Nordic countries increasingly use molecular profiling within hematologic cancer pathways. The region also benefits from strong clinical research activity and pharmaceutical trial infrastructure, which support repeated MRD assessment as an endpoint for treatment response.

European growth is nevertheless affected by differences in reimbursement and laboratory access between individual countries. Western European health systems generally have greater sequencing availability than several smaller or lower-spending markets, creating uneven penetration. Germany represented approximately 22.3% of one recent European market assessment, reflecting its large academic hospital base and hematology research ecosystem. Companies from the supplied competitive landscape, including Cergentis B.V. in the Netherlands, ICON plc in Ireland and Inivata in the United Kingdom, strengthen the region's role in assay development, clinical research and precision-oncology services.

Asia-Pacific

Asia-Pacific is positioned as the fastest-growing regional market, with recent industry projections indicating expansion of approximately 14.2% CAGR. Growth is supported by increasing cancer incidence, improvements in hospital infrastructure and greater availability of sequencing across China, Japan, India, South Korea and Australia. Flow Cytometry still represented approximately 41.8% of regional technology activity in a recent 2025 assessment, showing that established hematology testing remains important. However, the rapid creation of clinical genomics laboratories is making NGS-based MRD assessment increasingly accessible, particularly in major metropolitan cancer centers.

China is expected to remain the largest Asia-Pacific contributor and represented approximately 44.8% of regional activity in one recent assessment. India is also emerging as a high-growth market, with forecasts indicating approximately 15.5% CAGR through the early 2030s as private laboratory networks and tertiary oncology centers expand molecular testing. Japan contributes through sophisticated diagnostics infrastructure and the presence of Sysmex Corporation within the supplied competitive landscape. The principal regional opportunity lies in moving MRD testing beyond a limited number of academic centers into larger networks of hospitals and diagnostic laboratories.

Latin America

Latin America remains an emerging MRD testing region where adoption is concentrated in private hospital systems, academic cancer centers and reference laboratories. Brazil and Mexico account for a substantial proportion of regional molecular-diagnostics capacity, while specialized oncology institutions increasingly incorporate Flow Cytometry and PCR into leukemia monitoring. NGS penetration remains lower because sequencing infrastructure and reimbursement are less consistent, although declining sequencing costs and centralized testing models are improving access. Across many regional markets, advanced molecular testing remains available to fewer than 50% of patients treated outside major urban oncology centers, highlighting significant long-term expansion potential.

Regional growth is expected to accelerate as cancer programs prioritize earlier recurrence detection and precision medicine. Centralized laboratories can serve multiple hospitals from a single sequencing facility, reducing the requirement for every oncology center to maintain complex NGS infrastructure. This hub-and-spoke model is particularly relevant for countries where populations are distributed across large geographic areas. Over the 2026-2035 period, adoption is expected to progress from predominantly hematologic MRD toward selective solid-tumor monitoring as clinical evidence strengthens and blood-based testing reduces dependence on repeated invasive sampling.

Middle East & Africa

The Middle East & Africa currently represents a smaller share of global MRD testing but contains distinct high-growth healthcare markets. Gulf countries are investing in genomic medicine, oncology centers and laboratory automation, while South Africa maintains established academic hematology expertise. Access remains highly uneven across the broader region, with some assessments indicating that only around 25% of laboratories across lower-resource African and selected developing markets have access to MRD-compatible advanced testing infrastructure. This limitation keeps sophisticated NGS testing concentrated in a relatively small number of tertiary centers.

Long-term expansion will depend on laboratory investment, workforce development and broader reimbursement for molecular oncology. Flow Cytometry and PCR are likely to remain important entry technologies because they can use established hematology and molecular laboratory infrastructure, while NGS adoption will initially concentrate in national reference centers. Regional governments pursuing genomic medicine programs could gradually reduce the infrastructure gap during the next 5-10 years. Partnerships between international diagnostic companies and local laboratory operators are also expected to improve sample logistics, training and standardized MRD reporting.

List of Top MRD (Minimal Residual Disease) Testing Companies

• Cergentis B.V. (Netherlands)
• Natera (United States)
• NeoGenomics Laboratories (United States)
• ICON plc (Ireland)
• Asuragen (United States)
• Invivoscribe (United States)
• Bio-Rad Laboratories (United States)
• ARUP Laboratories (United States)
• Inivata (United Kingdom)
• Sysmex Corporation (Japan)
• Guardant Health (United States)
• Adaptive Biotechnologie (United States)
• Mission Bio (United States)
• LabCorp (United States)
• Quest Diagnostics (United States)
• Opko Health (United States)
• ArcherDX (Invitae) (United States)

Top 2 Companies Market Share

Natera: Natera is among the most influential companies in contemporary molecular residual disease testing, with its position strengthened by personalized circulating tumor DNA technology and the 2026 U.S. companion diagnostic milestone. The company's oncology strategy focuses heavily on serial testing, creating multiple potential tests per patient rather than a one-time diagnostic interaction. Its personalized approach can monitor patient-specific tumor alterations following initial tissue characterization, and tissue-free development programs are intended to address patients without suitable archived tumor material. In 2026, regulatory recognition of blood-based MRD for treatment selection significantly strengthened its competitive position in precision oncology.

Guardant Health: Guardant Health is another leading supplied company in blood-based MRD testing, with its competitive strategy centered on liquid biopsy, tissue-independent workflows and expansion across solid tumors. The company's MRD technology is positioned for recurrence surveillance following curative-intent treatment and benefits from a broader circulating tumor DNA ecosystem. Blood-based monitoring can be repeated several times during follow-up without requiring additional tumor biopsies, making the approach attractive for longitudinal surveillance. Competition between leading providers is increasingly focused on detection limits approaching 1 part per million, tumor coverage, clinical evidence and integration into therapeutic decision pathways.

Investment Analysis

Investment in MRD testing is increasingly directed toward sequencing depth, bioinformatics automation, clinical validation and liquid biopsy infrastructure rather than conventional laboratory expansion alone. The strongest commercial rationale comes from recurring testing: a cancer patient may undergo an initial baseline assessment followed by 3, 4 or more longitudinal tests during treatment and surveillance. This repeat-use model expands lifetime testing volume while creating large longitudinal molecular datasets. With approximately 18.6 million cancer survivors in the United States during 2025 and an expected increase to approximately 22 million by 2035, investors are focusing on platforms capable of scaling serial testing across both hematologic malignancies and solid tumors.

Asia-Pacific also presents a significant infrastructure investment opportunity, supported by regional growth projections around 14.2% CAGR and India-specific estimates around 15.5%. Capital deployment is moving toward centralized sequencing laboratories, automated sample preparation, cloud-supported bioinformatics and partnerships with hospital oncology networks. At the technology level, Flow Cytometry retains approximately 40-43% share across multiple regional assessments, but incremental investment is increasingly targeting NGS because of its ability to monitor hundreds or thousands of patient-specific variants. Companies that combine high sensitivity with lower sample requirements and faster turnaround are likely to receive disproportionate strategic attention through 2035.

New Product Development

New product development is concentrated on increasing sensitivity while simplifying clinical workflows. The newest MRD assays are moving beyond relatively narrow mutation panels toward personalized NGS systems capable of following hundreds or more than 1,000 tumor-associated variants. This is a significant change from several first-generation blood-based approaches that monitored approximately 16-50 variants. Developers are also combining genomic alterations with methylation and DNA-fragment characteristics to improve signal detection in low-shedding tumors. Analytical targets are moving toward tumor fractions around 0.01% and, for selected ultra-sensitive platforms, approximately 1 cancer-associated DNA fragment among 1 million background fragments.

Product development is simultaneously shifting toward tissue-free testing and clinically actionable companion diagnostics. Tissue-free approaches can reduce dependence on archived surgical material and potentially shorten onboarding for patients whose tumor samples are unavailable. Selected tissue-free approaches have demonstrated detection capability corresponding to approximately 86% of tumor-informed performance in comparative evaluations. The other major development direction is therapy selection: the 2026 approval of a personalized MRD companion diagnostic in muscle-invasive bladder cancer established a regulatory precedent for using residual disease status to identify patients for specific post-surgical therapy. This precedent is likely to accelerate development programs in colorectal, lung, breast and other solid tumors.

Five Recent Developments

• May 2026: Natera achieved a major regulatory milestone when Signatera CDx received U.S. approval as a companion diagnostic for patients with muscle-invasive bladder cancer, marking the first approved personalized blood-based MRD application directly linked with treatment selection after surgery.
• June 2026: Natera entered a strategic oncology collaboration involving Signatera assessment of clinical-trial samples in a Phase 2 colorectal cancer program, expanding use of personalized MRD testing for molecular response analysis and reinforcing the role of serial ctDNA measurements in drug-development studies.
• March 2026: Guardant Health highlighted an expanded precision-oncology research program involving 28 scientific abstracts, including work examining broader utility of Guardant Reveal during MRD surveillance, demonstrating increasing industry investment in clinically validated blood-based monitoring across multiple cancer settings.
• January 2025: Natera outlined an expanded oncology innovation roadmap centered on molecular residual disease and early cancer detection, including tissue-free testing development intended to increase eligibility among patients lacking suitable tumor tissue and broaden MRD accessibility beyond conventional tumor-informed workflows.
• September 2024: Guardant Health advanced its liquid-biopsy MRD strategy for colorectal cancer using enhanced sequencing and tumor-associated molecular signals, strengthening competitive development in post-treatment surveillance as the industry increasingly targeted detection thresholds substantially below 0.1% circulating tumor DNA.

Report Coverage

The MRD (Minimal Residual Disease) Testing Market analysis covers the 2026-2035 forecast period using 2025 as the principal baseline and evaluates the supplied technology categories of Flow Cytometry, Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS). It also assesses the supplied applications of Specialty Clinics and Hospitals, Diagnostic Laboratories and Research Institutions. The analysis considers technology sensitivity, clinical workflow, cancer surveillance requirements, regulatory developments, laboratory infrastructure and regional adoption. Flow Cytometry currently represents approximately 40-43% of technology activity across several major markets, while NGS is expected to record the fastest technology expansion as ultra-sensitive liquid biopsy and personalized molecular monitoring gain clinical acceptance.

Geographic coverage includes North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, with North America currently accounting for approximately 46.2% of global activity in recent assessments and Asia-Pacific demonstrating growth indicators around 14.2% CAGR. Competitive coverage incorporates all 17 supplied companies and examines positioning across molecular assays, laboratory services, liquid biopsy, sequencing, Flow Cytometry, clinical research and precision oncology. The analysis additionally addresses the approximately 2.04 million new U.S. cancer cases estimated for 2025, the 18.6 million U.S. cancer survivors requiring increasingly sophisticated surveillance, regulatory movement toward MRD-guided treatment and the growing use of longitudinal molecular measurements within oncology trials and routine patient management.